Artificial intelligence is becoming an important layer in clinical genomics, but its role must be understood carefully.

Genomic interpretation is not a simple data-processing task. It involves variant biology, disease mechanism, population frequency, clinical phenotype, therapeutic relevance, evidence strength, and evolving guidelines. A sequencing pipeline can identify variants, and an AI system can help organize knowledge around them — but the clinical meaning of a variant still depends on context. This is why expert review remains central to responsible AI in genomics.

Genomic Interpretation is Context-Dependent

A genomic variant does not have one universal meaning. Its interpretation can change based on whether it is germline or somatic, whether it is found in a cancer sample or inherited disease setting, whether the gene has an established disease association, whether the variant affects protein function, and whether the evidence is strong enough to influence clinical reporting.

For example, a DNA-repair pathway alteration may have therapeutic relevance in one tumour type, uncertain significance in another, and hereditary implications if present in the germline. Similarly, a rare variant in a child with suspected genetic disease must be interpreted alongside phenotype, inheritance pattern, segregation evidence, and gene-disease validity.

For example, a DNA-repair pathway alteration may have therapeutic relevance in one tumour type, uncertain significance in another, and hereditary implications if present in the germline. Similarly, a rare variant in a child with suspected genetic disease must be interpreted alongside phenotype, inheritance pattern, segregation evidence, and gene-disease validity.

AI can assist in connecting these data points, but it cannot be allowed to treat every detected variant as clinically equivalent. The science of genomics requires interpretation, not just prediction.

The role of AI should be evidence organization

The most immediate value of AI in genomics is not autonomous decision-making. It is structured evidence organization. A genomic reviewer often needs to evaluate multiple layers of information:

• variant quality and sequencing confidence
• population frequency
• predicted functional impact
• prior classifications
• gene-disease association
• tumour or phenotype relevance
• inheritance model
• therapeutic or pharmacogenomic implications
• guideline and literature support
• uncertainty and limitations

This review is time-intensive and highly dependent on expertise. AI can help by prioritizing variants, summarizing evidence, mapping findings to disease context, structuring report sections, and reducing repetitive manual effort. In that sense, AI becomes a scientific workflow accelerator. But acceleration is not the same as clinical authority.

The final interpretation must still be reviewed by qualified experts who understand both the molecular evidence and the clinical scenario.

The risk of AI is Over-Interpretation

One of the most important risks in genomic AI is not simply that it may be wrong. It is that it may sound too confident. Clinical genomics contains large zones of uncertainty. Variants of uncertain significance, emerging biomarkers, limited functional evidence, conflicting database entries, and evolving therapeutic associations are common.

A responsible genomic report must distinguish between:

• established evidence
• guideline-backed actionability
• emerging evidence
• research-level associations
• uncertain findings
• non-reportable or low-confidence signals

If AI compresses these distinctions into a polished interpretation, it can create false confidence. That is especially dangerous in oncology, rare disease, hereditary risk, and pharmacogenomics, where the consequences of over-interpretation can affect treatment choices, family counselling, or patient anxiety. Expert review acts as the scientific control layer. It ensures that the report does not overstate what the evidence can support.

Responsible AI needs traceability

For AI to be useful in genomics, its outputs must be traceable. A reviewer should be able to see why a variant was prioritized, which sources were used, what evidence level was assigned, whether the interpretation is consistent with guidelines, and where uncertainty remains.

This requires more than a language model producing text. It requires a governed interpretation architecture built around:

• curated evidence sources
• version-controlled knowledge bases
• guideline-aware logic
• audit trails
• reviewer sign-off
• transparent evidence links
• clear separation between evidence and interpretation
• continuous validation against expert-reviewed cases

In clinical genomics, explainability is not a cosmetic feature. It is fundamental to scientific trust.

Why expert review is not a bottleneck to remove

It is tempting to see expert review as the slow part of the workflow. But in genomics, expert review is not merely an operational checkpoint. It is part of the scientific method. Experts evaluate whether the data quality is sufficient, whether the variant is biologically plausible, whether the evidence is clinically relevant, and whether the report language is responsible.

This is particularly important because genomic knowledge is not static. Variant classifications change. New therapies emerge. Population databases expand. Guidelines are revised. Evidence that was uncertain today may become clinically relevant tomorrow — and vice versa.

A responsible AI system must therefore support ongoing expert review rather than bypass it. The goal should be to reduce unnecessary manual burden while preserving scientific judgment.

The Indian Context: Scaling genomics without diluting rigor

For India, this distinction is critical. As genomic testing expands, interpretation capacity will become one of the key constraints. Advanced genomic interpretation is still concentrated in specialized centers, while many smaller and mid-sized diagnostic labsmay not have access to large bioinformatics or clinical genomics teams.

AI can help distribute interpretation capability more widely. It can help labs produce more standardized, evidence-linked, clinician-readable reports. It can support oncology, rare disease, hereditary risk, and pharmacogenomics workflows beyond a limited number of elite institutions. But this scale must not come at the cost of rigor.

India does not need automated genomic reports that are faster but less trustworthy. It needs responsible genomic intelligence platforms that allow expert knowledge to scale while maintaining evidence traceability, reviewability, and clinical accountability. That is the balance responsible AI must achieve.

AI-Assisted, expert-led genomics

The future of clinical genomics should not be framed as AI replacing experts. A better model is AI-assisted, expert-led interpretation. AI should help with evidence retrieval, variant prioritization, pattern recognition, literature summarization, report structuring, and workflow consistency. Experts should remain responsible for clinical relevance, evidence judgment, uncertainty handling, and final interpretation.

This combination can improve speed without compromising safety. It can improve consistency without removing nuance. It can make genomic medicine more scalable without reducing it to automation.

Conclusion

AI will become an important part of genomic medicine, but its value will depend on how responsibly it is designed and used. In genomics, the challenge is not just to generate an interpretation. The challenge is to generate an interpretation that is scientifically defensible, evidence-linked, clinically contextual, and reviewable by experts.

Expert review is not a weakness in genomic AI. It is the mechanism that makes genomic AI clinically credible. The future belongs to platforms that can combine computational scale with scientific judgment — helping diagnostic labsand clinicians move faster, while keeping evidence, responsibility, and patient context at the canter.